L13: Tumor Immunology Flashcards Preview

Immunology > L13: Tumor Immunology > Flashcards

Flashcards in L13: Tumor Immunology Deck (23):

Tumor types

1.) Carcinomas: epithelial cells (most common CA)
2.) Sarcomas: muscle cells, fat cells or fibroblasts
3.) Lymphomas: solid tumors of lymphoid tissues
4.) Leukemias: lymphocytes and other hematopoietic cells


Characteristics of benign vs malignant tumors

1.) Benign: slow growth, differentiated cells, usually encapsulated, not fatal unless at critical site
2.) Malignant: undifferentiated cells, readily metastasize, usually fatal if untreated



- TSA: tumor specific antigens (only on CA cells) – not common
- TAA: tumor associated antigens (also on normal tissues)


Examples of TAAs

1.) AFP: alpha fetal protein produced by certain liver CAs
2.) Oncofetal antigens: expressed on fetal, but not adult tissues
3.) CEA: carcinoembryonic antigen is high in colon CA and smokers


Viral oncogenic antigens. Where are these presented?

1.) DNA viruses: EBV, HPV and HBV
2.) RNA viruses: HTLV (adult CD4+ T cell leukemia/lymphoma)
• presented on class I MHC


Antigen(s) specific for B cell leukemias and lymphomas

- CD10 and immunoglobulin


Antigen(s) specific for T cell leukemias and lymphomas

- IL-2 receptor (alpha chain), TCR, CD45R and CD4/8


Antigen(s) specific for melanomas

- S-100


Antigen(s) specific for carcinomas

- epithelial derived tissue, therefore cytokeratins


Antibodies are the strongest form of immunity against tumors. True / False

- False, cell-mediated immunity is


What type of tumors are CTLs produced against?

- Carcinomas, sarcomas and virus-induced tumors


What are TIL’s?

- Tumor-infiltrating lymphocytes, which are mainly of CTL subtype that are found in solid tumors


What type of tumors are NK cells produced against?

- Tumors of hematopoietic origin and virus-induced


CTLs are the best defense against virus-induced tumors. True / False

- True. NK cells can also lyse these cells, but CTLs are the best


Mechanism of NK cells destroying tumor cells

1.) ADCC with some tumors (requires antibody)
2.) Downregulation of class I MHC in some tumors (which normally acts as inhibitory signal)
3.) LAK cells – subset of NK cells that are exposed to high levels of IL-2 and have T lymphocyte homology. They enhance killing of various tumor cells as well as recognize them better.


What cytokines enhance NK cells in their lysis of tumor cells?

- TNF-alpha, IL-2


Action of macrophage in killing tumor cells?

1.) ADCC
2.) Release of TNF-alpha (downstream effect on NK cells +…) directly lyses tumor cells (? Free radicals, hemorrhagic necrosis of tumor blood vessels?)


How do tumor cells attempt to evade the immune system?

1.) Lack of MHC expression (particularly class I)
2.) Induce tolerance via absence of costimulatory molecules
3.) Failure to produce tumor antigen
4.) Anti-tumor abs acts as blocking factors
5.) Antigen shed by tumor cells
6.) Tumor antigens masked by mucopolysaccharides
7.) Tumor releases immunosuppressive substances – TGF-beta
8.) Creation of immunoprivileged site by encasement in collagen and fibrin


Types of immunotherapies available against tumors

1.) Tumor vaccines: vaccinate with tumor cells treated to increase immunogenicity or DCs loaded with tumor antigens. HBV vaccine decreases incidence of hepatocellular carcinoma
2.) Antibody therapies: lysis by ADCC/complement, abs against growth factors (Her2-neu – herceptin)
3.) Immunoconjugates: abs coupled to toxic substance directed towards tumor-specific antigen using Fab2 fragments
4.) Bi-specific antibodies: genetically engineering abs that recognize tumor antigens and immune system cells
5.) Purging bone marrow of tumor cells (autologous bone marrow transplantation in B cell lymphoma pts)
6.) LAK cell therapy: NK cells cultured in high levels of IL-2 – differentiate into LAK cells then reinfused back into pt
7.) TIL therapy: leukocytes from solid tumors cultured with IL-2 and given back to pt
8.) Cytokine therapy
a.) IL-2: generates LAK cells, activates CTLs
b.) TNF-alpha: anti-tumor effects, but potential to develop septic shock
c.) IFN-alpha: increases NK cell activity and increases class I MHC expression on tumors
d.) Transfection of cytokine genes into pt tumor cells: immune stimulation locally instead of systemically


A patient is diagnosed with diffuse large B cell lymphoma. A specific therapy was used that targeted the surface immunoglobulin that was expressed by his tumor cells. The tumor cell immunoglobulin is a type of _______ antigen.
2.oncogenic viral
If an anti-idiotypic antibody was used to treat the lymphoma patient, it would recognize the _____ region of the tumor cell immunoglobulin?
3.Fc receptor

- tumor-specific
- Fab


What is the most dreaded, yet all-to-common, outcome of the treatment of B cell lymphoma with anti-idiotypic antibodies?
1.Secondary tumors unrelated to the B cell lymphoma
2.Neutralizing antibodies against the therapy antibody
3.Tumor growth outpaces the amount of therapy antibody available
4.Tumor variants that don’t bind the therapy antibody

- 4.


In an experimental attempt to treat a patient with disseminated colon cancer, cancer cells were transfected with a gene that increased the expression of class I MHC molecules. Which component of the immune response likely would participate in killing of the tumor cells?
1.Dendritic cells
2.Cytotoxic T cells
4.Natural killer cells

- 2.


A patient had a particularly aggressive cancer. A sample of the patient’s tumor revealed that the cells produced a large amount of IL-10. This likely provided a fair degree of protection from the immune system by shifting the patient immune response toward a _____ type of response.

- 2.